Polymorphisms in NFKB1 and NFKBIA genes modulate the risk of developing prostate cancer among han chinese

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 1707-1715

  Han, Xiao ^a   Zhang, Jia Jun ^a   Yao, Nan ^a   Wang, Gang ^b   Mei, Juan ^a   Li, Bo ^c   Li, Chao ^d   Wang, Zi An ^a  

^a BENGBU MEDICAL COLLEGE   (China)

^b The Third People's Hospital of Bengbu   (China)

^c Armor Academy of the Chinese People's Liberation Army   (China)

^d Bengbu First Peoples Hospital   (China)

Author keywords

Asian continental ancestry group; Association; Genetic; Genetic association studies; Genotype; Polymorphism

Indexed keywords

I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; I KAPPA B; NFKB1 PROTEIN, HUMAN; NFKBIA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; GENE FREQUENCY; GENETIC ANALYSIS; GENOTYPE; HAN CHINESE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; CHINA; GENETIC ASSOCIATION STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; I-KAPPA B PROTEINS; MALE; MIDDLE AGED; NF-KAPPA B P50 SUBUNIT; NF-KAPPAB INHIBITOR ALPHA; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSTATIC NEOPLASMS;

EID: 84935892901     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.893471     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. Cancer J Clin, 2013; 63(1): 11-30
2. McCracken M, Olsen M, Chen MS Jr et al: Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. Cancer J Clin, 2007; 57(4): 190-205
3. Ferlay J, Soerjomataram I, Ervik M et al: GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr
4. Murphy AB, Akereyeni F, Nyame YA et al: Smoking and prostate cancer in a multi-ethnic cohort. Prostate, 2013; 73(14): 1518-28
5. Leitzmann MF, Rohrmann S: Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol, 2012; 4: 1-11
6. Lichtenstein P, Holm NV, Verkasalo PK et al: Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med, 2000; 343(2): 78-85
7. Patnala R, Clements J, Batra J: Candidate gene association studies: a comprehensive guide to useful in silico tools. BMC Genetics, 2013; 14: 39
8. Kwon JM, Goate AM: The candidate gene approach. Alcohol Res Health, 2000; 24(3): 164-68
9. Kryvenko ON, Jankowski M, Chitale DA et al: Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer. Mod Pathol, 2012; 25(7): 1023-32
10. Sfanos KS, Isaacs WB, De Marzo AM: Infections and inflammation in prostate cancer. Am J Clin Exp Urol, 2013; 1(1): 3-11
11. Sfanos KS, Hempel HA, De Marzo AM: The role of inflammation in prostate cancer. Adv Exp Med Biol, 2014; 816: 153-81
12. Sfanos KS, De Marzo AM: Prostate cancer and inflammation: the evidence. Histopathology, 2012; 60(1): 199-215
13. Wang L, Xie PG, Lin YL et al: Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy. Med Sci Monit, 2014; 20: 1363-68
14. Lin YL, Xie PG, Wang L, Ma JG: Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy. Med Sci Monit, 2014; 20: 1376-82
15. Mohd Suzairi MS, Tan SC, Ahmad Aizat AA et al: The functional-94 insertion/ deletion ATTG polymorphism in the promoter region of NFKB1 gene increases the risk of sporadic colorectal cancer. Cancer Epidemiol, 2013; 37(5): 634-38
16. Shiels MS, Engels EA, Shi J et al: Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk. Cancer, 2012; 118(22): 5630-36
17. Cheng CW, Su JL, Lin CW et al: Effects of NFKB1 and NFKBIA gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathological features. PLoS One, 2013; 8(2): e56130
18. Curran JE, Weinstein SR, Griffiths LR: Polymorphic variants of NFKB1 and its inhibitory protein NFKBIA, and their involvement in sporadic breast cancer. Cancer Lett, 2002; 188(1-2): 103-7
19. Tan SC, Suzairi MS, Aizat AA et al: Gender-specific association of NFKBIA promoter polymorphisms with the risk of sporadic colorectal cancer. Med Oncol, 2013; 30(4): 693
20. White KL, Vierkant RA, Phelan CM et al: Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer. BMC Cancer, 2009; 9: 170
21. Shafi'i MSM, Shahpudin SNM, Mustapha MA et al: The genetic variation A>G at 3' UTR of nuclear factor kappa B 1 A (NFkB1A) influences susceptibility of sporadic colorectal cancer in Malaysian population. Int Med J, 2012; 19(2): 98-101
22. Zhang P, Wei Q, Li X et al: A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases susceptibility for prostate cancer. Cancer Genet Cytogenet, 2009; 191(2): 73-77
23. Kopp TI, Friis S, Christensen J et al: Polymorphisms in genes related to inflammation, NSAID use, and the risk of prostate cancer among Danish men. Cancer Genet, 2013; 206(7-8): 266-78
24. Oeckinghaus A, Ghosh S: The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol, 2009; 1(4): a000034
25. Tak PP, Firestein GS: NF-kappaB: a key role in inflammatory diseases. J Clin Invest, 2001; 107(1): 7-11
26. Naugler WE, Karin M: NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev, 2008; 18(1): 19-26
27. Lu S, Dong Z: Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells. Prostate, 2006; 66: 996-1004
28. Wise GJ, Marella VK, Talluri G, Shirazian D: Cytokine variations in patients with hormone treated prostate cancer. J Urol, 2000; 164: 722-25
29. Nakashima J, Tachibana M, Horiguchi Y et al: Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res, 2000; 6: 2702-6
30. Shariat SF, Andrews B, Kattan MW et al: Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology, 2001; 58: 1008-15
31. Karban AS, Okazaki T, Panhuysen CI et al: Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet, 2004; 13(1): 35-45
32. Abdallah A, Sato H, Grutters JC et al: Inhibitor kappa B-alpha (IkappaB-alpha) promoter polymorphisms in UK and Dutch sarcoidosis. Genes Immun, 2003; 4(6): 450-54